Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522285 | 0.96 | ALDH1A1 (0.39) | ALDH1A1NPSR1TP53KMT2AELANE | |
| SCHEMBL1522821 | 0.83 | ALDH1A1 (0.36) | ALDH1A1NPSR1TP53KMT2AELANE | |
| SCHEMBL1522918 | 0.80 | LMNA (0.39) | ALDH1A1TP53KMT2AELANEGAA | |
| SCHEMBL9910006 | 0.78 | ALDH1A1 (0.42) | ALDH1A1NPSR1TP53HPGDTSHR | |
| SCHEMBL12184419 | 0.78 | ALDH1A1 (0.42) | ALDH1A1NPSR1TP53HPGDTSHR | |
| SCHEMBL1523122 | 0.77 | KMT2A (0.36) | KMT2AELANEGAA | |
| SCHEMBL1523552 | 0.77 | FEN1 (0.33) | ALDH1A1NPSR1TSHRKMT2AELANE | |
| SCHEMBL1271477 | 0.75 | EGLN1 (0.37) | ALDH1A1HPGDTSHRKMT2AELANE | |
| SCHEMBL13989010 | 0.75 | KMT2A (0.36) | HPGDTSHRKMT2AELANEUSP2 | |
| SCHEMBL2453991 | 0.74 | PGR (0.55) | ALDH1A1NPSR1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361913-A1 | Anti-infective agents | Abbott Laboratories (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7902203-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1560827-B1 | ANTI-INFECTIVE AGENTS | ABBOTT LAB (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097492-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ALDH1A1 1434/4885NPSR1 4323/4885TP53 3666/4885 |
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ALDH1A1 1434/4885NPSR1 4323/4885TP53 3666/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | ALDH1A1 891/4885NPSR1 4037/4885TP53 3890/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | ALDH1A1 1592/4885NPSR1 4146/4885TP53 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.